Morgan Stanley analyst Dara Mohsenian raised the firm’s price target on Colgate-Palmolive (CL) to $100 from $87 and keeps an Overweight rating on the shares. Solid Q4 EPS upside and a sequential organic sales growth recovery confirm Q3 was a trough and 2026 guidance looks “conservative,” the analyst tells investors in a post-earnings note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CL:
- Colgate-Palmolive: Strengthening Earnings Visibility and Long-Term Growth Through Premiumization and the 2030 Strategic Plan
- Colgate-Palmolive price target raised to $94 from $86 at Wells Fargo
- Colgate-Palmolive: Premium-Valued Emerging Markets and Pet Nutrition Strength Support Buy Rating and Upside into 2026
- Colgate-Palmolive price target raised to $94 from $91 at Goldman Sachs
- Colgate-Palmolive Navigates Mixed Signals in Earnings Call